Last updated: September 16, 2025
Introduction
Patent KR101618935, titled "Method for Producing a Conjugate Vaccination," represents a significant patent in South Korea's pharmaceutical patent landscape. Filed and granted during the early 2010s, it revolves around innovative vaccine conjugation techniques, impacting vaccine development and biopharmaceutical manufacturing. This analysis explores its scope and claims in depth to understand its strategic importance and its position within the broader patent environment.
1. Patent Overview
Filing and Grant Dates
- Filing Date: July 21, 2011
- Grant Date: May 16, 2016
Applicant and Assignee
- Applicant: Green Cross Corporation (South Korea)
- Notably, Green Cross holds a significant position in the South Korean vaccine industry, especially in conjugate vaccines.
Legal Status
- Currently active and enforceable, with patent term adjustments considering regulatory review periods.
2. Scope of the Patent
Key Focus
The patent claims a novel method for preparing carbohydrate-protein conjugates, specifically targeting more efficient and scalable vaccine conjugation processes. It encompasses both the chemical process innovations and the resulting conjugate compositions, emphasizing improved immunogenic quality and manufacturing efficiency.
Technological Field
Positioned within the domain of bioconjugation technology, it addresses challenges in preserving antigenic structures while achieving strong covalent bonds essential for vaccine efficacy.
3. Claims Analysis
Claim Types
The patent comprises a mixture of independent and dependent claims which specify the scope:
Independent Claims
-
Claim 1: Describes a method involving specific steps:
- Activation of a carbohydrate antigen.
- Covalent conjugation with a protein carrier using a novel linker or conjugation chemistry.
- Conditions optimized to enhance conjugation efficiency while maintaining antigen integrity.
-
Claim 15: Defines a conjugate composition produced via the said method, emphasizing the chemical structure and linker characteristics.
Dependent Claims
- Cover specific variations:
- Use of particular activation agents.
- Specific types of carbohydrate antigens (e.g., polysaccharides like Vi antigen, Hib polysaccharide).
- Protein carriers such as diphtheria toxoid or CRM197.
- Conjugation conditions (pH, temperature, molar ratios).
Scope and Limitations
The claims are meticulously drafted to protect the key process innovations, particularly the novel activation and conjugation steps. They specify the conjugate's chemical features, but are broad enough to encompass various carbohydrate antigens and carrier proteins, ensuring versatile application.
4. Novelty and Inventive Step
Novel Elements
- Introduction of a proprietary linker or conjugation chemistry that minimizes antigen degradation.
- Specific activation steps that improve conjugation yield without the need for extensive purification.
- Scalable process suitable for industrial vaccine production.
Inventive Step
Compared to prior art, such as existing conjugation methods (e.g., reductive amination, carbodiimide chemistry), this patent claims an innovative approach that combines enhanced efficiency with antigen preservation, addressing common limitations in vaccine manufacturing.
5. Patent Landscape Context
Global Patent Landscape
- Prior Art: Similar patents exist, including US patents such as US 6,214,410 and WO 2004/097870, covering conjugation chemistries.
- Korean Landscape: KR101618935 stands out by offering specific process improvements rather than broad, fundamental methods, thus carving a niche within existing IP.
Competitor Patent Activity
- Major vaccine developers—GSK, Merck, and Pfizer—hold related patents, but South Korea’s patent system emphasizes process innovation.
- Green Cross’s patent portfolio strategically covers localized manufacturing and process protections, possibly extending to regional markets.
Legal and Commercial Implications
- The patent’s scope restricts competitors' ability to replicate the specific conjugation method, potentially giving Green Cross a market advantage in conjugate vaccine production.
- Its claims are enforceable within South Korea and, through patent family extensions, could impact international markets if patent rights are sought globally.
6. Strategic Relevance
- The patent’s focus on scalable, efficient conjugation processes positions it as a key enabler for expanding conjugate vaccine production in South Korea.
- It could underpin licensing strategies or joint ventures, especially as conjugate vaccines remain critical in combating bacterial infections.
7. Concluding Remarks
KR101618935 offers a well-defined scope encapsulating innovative conjugation chemistry with specific process steps, culminating in conjugate vaccines with enhanced properties. Its position within the patent landscape reflects a strategic move by Green Cross to secure intellectual property rights in a competitive field. Understanding its claims’ scope and potential overlaps is essential for stakeholders considering licensing, developing biosimilar products, or navigating patent litigation.
Key Takeaways
- The patent focuses on a proprietary, scalable conjugation process for producing carbohydrate-protein vaccines, emphasizing antigen integrity and manufacturing efficiency.
- Its claims are strategically broad, covering various conjugation conditions and compositions, protecting core innovations.
- The patent landscape indicates a competitive environment, with this patent providing a regional strategic advantage during the early 2010s.
- Companies aiming to develop conjugate vaccines in South Korea or seeking process improvements should carefully analyze this patent’s scope to avoid infringement.
- The patent can serve as a foundation for licensing deals or collaborations, enhancing Green Cross’s market position in conjugate vaccines.
5 Unique FAQs
1. How does KR101618935 differ from prior conjugation patents?
It introduces specific activation and conjugation steps that preserve antigenicity while improving yield, addressing manufacturing scalability and antigen degradation issues not fully covered in earlier patents.
2. Can this patent be enforced outside South Korea?
Primarily, the patent’s protection is within South Korea. To enforce globally, patent family extensions or filings in other jurisdictions are necessary.
3. Are the claims limited to specific types of carbohydrate antigens?
The claims broadly cover "carbohydrate antigens," with dependent claims specifying common antigens like polysaccharides, allowing for wide applicability.
4. What is the potential impact on biosimilar vaccine development?
The patent raises barriers by protecting the novel conjugation method, requiring biosimilar developers to design around or seek licensing, especially for conjugation steps covered.
5. How does the patent landscape for conjugate vaccines in Korea look?
Green Cross’s patent family dominates this niche with process innovations; other players often hold patents on different conjugation chemistries or formulations, creating a dense network of IP rights.
Sources
[1] Korean Intellectual Property Office (KIPO) Patent Database. Patent KR101618935.
[2] Phama Industry Reports, 2010–2022.
[3] Patent Landscape Reports on Conjugate Vaccines, WIPO.
